Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02-14.

Autor: Auliac JB; Chest Department, Hopital de Mantes La Jolie, Mantes-la-Jolie, France., Dô P; Oncolgy Department, Centre Francois Baclesse, Caen, France., Bayle S; Chest Department, Institut de Cancérologie, Saint-Priest-en-Jarez, France., Doubre H; Chest Department, Hôpital Foch, Suresnes, France., Vinas F; Chest Department, Centre Hospitalier Intercommunal de Créteil, Créteil, France., Letreut J; Chest Department, Hopital d'Aix-en-Provence, Aix-en-Provence, France., Falchero L; Chest Department, Hopital de Villefranche, Villefranche, France., Hauss PA; Chest Department, Hopital D'Elbeuf, Elbeuf, France., Thomas P; Chest Department, Hopital de Gap, Gap, France., Chouaid C; Chest Department, Centre Hospitalier Intercommunal de Créteil, Créteil, France. christos.chouaid@chicreteil.fr.
Jazyk: angličtina
Zdroj: Advances in therapy [Adv Ther] 2019 Aug; Vol. 36 (8), pp. 2161-2166. Date of Electronic Publication: 2019 Jun 01.
DOI: 10.1007/s12325-019-01001-9
Abstrakt: Background: Mutation of human receptor tyrosine kinase epidermal growth factor receptor-2 (HER2) is a rare event, found in approximately 1% non-small cell lung cancers (NSCLC). The objective was to investigate the clinical characteristics and management of HER2-mutated NSCLCs in a real-life setting.
Methods: This multicenter study described NSCLCs harboring HER2 mutations diagnosed between January 2012 and December 2014, according their clinical characteristics, management, and outcomes: response rate (RR), progression-free survival (PFS), and overall survival (OS).
Results: Thirty patients were included: 66.7% women; median age 65.2 ± 12 years; never or former smokers 73.3%. Of the stage IV patients (n = 23), 86% received first-line platin doublet chemotherapy: RR 61.5% and PFS 6.7 (95% CI 5.9-9.5) months; 52.1% received a second-line therapy: RR 18.2% and PFS 4.9 (95% CI 2.5-11.9) months. Median OS of stage IV was 10.7 months and 2-year OS was 27.2% (95% CI 11.7-63.2). All patients with stage I-III NSCLCs were alive at 2 years.
Conclusion: The rarity of HER2-mutated NSCLCs requires specific studies.
Databáze: MEDLINE
Externí odkaz: